A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to find out why I rate PTGX is a Buy.

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

Response rates continued to improve through Week 24 where 86.4% of adolescents achieved IGA 0/1 (clear or almost clear skin) and 88.6% achieved PASI 90.1 Further, at Week 24, 75% of adolescents ...

The co-primary efficacy objectives of this study are the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) and the proportion of ...

Across both clinical trials and timepoints, significantly more Sotyktu-treated patients achieved a sPGA score of 0/1, PASI 75 response and PASI 90 response.

Subgroup analysis showed no significant difference in the reduction of PASI scores between 320 mg q4w dosage and q8w dosage (RR = 1.00; 95% CI = 0.96–1.03).

Of those on placebo, 4.4% met the PASI 90 score. Response rates continued to ramp up at week 24, when 74.1% of patients on icotrokinra had clear or almost clear skin and 64.9% achieved PASI 90.

A lower PASI when therapy ends (HR, 1.03; 95% CI, 1.01-1.05). This model had good predictive and discriminative ability. The sensitivity analysis showed similar results to the primary analysis.

Spearman correlations between the PASI score and host genes were separately estimated for lesional and non-lesional groups. This revealed functions related to antiviral response in both groups.

A PASI 90 score signifies that 90% of skin surface area is cleared. The proportion of patients who achieved a PASI 100 score, signifying total clearance, approached 70% at 4 years in the group ...